Use of PITX2 nucleic acids to improve the treatment of breast cell proliferative disorders

摘要

Use of i) a nucleic acid molecule consisting of a sequence of at least 18 bases of the length of one of the sequences selected from the group consisting of SEQ ID NO: 411, 412, 515, 516, 685, 686, 789 and 790, and complementary sequences thereof, ii) an oligonucleotide or PNA-oligomer consisting of at least one base sequence having a length of at least nucleotides that is complementary or identical to one of the nucleic acid sequences according to SEQ ID NO. 515, 686 and 789, iii) a set of oligonucleotides according to ii), or iv) a kit comprising a bisulfite reagent ( = bisulfite, hydrogen sulfite) as well as oligonucleotides and / or PNA-oligomers according to ii) or iii) for the analysis of the PITX2 mutilation pattern to predict the response of patients with breast cell proliferative contrast ornaments to a complementary therapy, comprising one or more drugs directed to the estrogen receptor pathway or they are involved in the metabolism, production or secretion of estrogen, in which said one or more drugs are selected detamoxifene, aromatase inhibitors, selective modulators of estrogen receptors and LH-RH analogues and in which said drugs block the effects of estrogens on cancer cells or reduce serum estrogen levels.